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ABSTRACT
Iran is growing fast in production of science and technology in the world. Based on experts’ 
opinion and reports of the Institute for Scientific Information (ISI), SCImago Journal and 
Country Rank, and Scopus it is concluded that the scientific field of Pharmacology Toxicology 
Pharmaceutics in Iran is growing very fast with great impact on the country science growth. 
Regarding various elements that have been involved in growth of sciences in Iran, focusing on 
quality of researches by the proposed methods in the present essay would be the key element of 
success in future. 
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The fact that Iran in the recent years is growing 
rapidly in terms of science and technology 
resuscitating its impressive history in science over 
the very ancient years where scientists like Razi and 
Ebn-E-Sina and Farabi conveyed unique inventions, 
ideas, and discoveries to the world (1) Recent report 
of NewScientist (2) about essay of UK’s Royal 
Society (3) indicates that Iran’s scientific output rose 
18-fold between 1996 and 2008, from 736 published 
papers to 13,238 meaning that Iran has the fastest 
rate of increase in scientific publication in the world. 
Growth of Iranian science production has been ever 
underestimated because some of Iranian publications 
have not been recorded in scientometric databases 
and thus much higher records must be expected 
(4). According to The Royal Society report, Iran 
designed a comprehensive plan for science focusing 
on higher education and strengthening the links 
between industry and academia. In addition, Iran 
has allocated a big fund for nanotechnology research 
and boosted investment in research to 4% of GDP 
(0.59% of GDP in 2006), and is increasing found for 
education to 7% of GDP by 2030 (5.49% of GDP in 
2007 (3).
Reviewing Scopus/Elsevier reveal that (5), a total 
of 133,325 scientific papers have been produced by 
Iranian scientists mainly in international journals 
(4) in the last 40 years, of which, almost 25% 
were  categorized  in  the  field  of  Pharmacology, 
Toxicology and Pharmaceutics (PTP). Data from 
Scopus also indicate a very rapid growth in PTP 
reaching from 3 indexed papers in 1972 to 1421 in 
2010 meaning a 474-times growth in the number 
of  publication  only  in  the  field  of  PTP.  Most  of 
publications were original articles and only a few 
were reviews or editorials. When data are searched 
for the keywords, it is evident that most of studies 
in the field of PTP were carried out in animals, in 
vitro and non-clinical models and few were clinical 
trials. Also, by categorizing data of PTP according 
to affiliation, it is found that Tehran University of 
Medical Sciences (TUMS) is ranked first followed by 
University of Tehran, Islamic Azad University, and 
then Shahid Beheshti Medical University (5). Data 
from Essential Science Indicator (6) indicate that 
TUMS has been listed among top 1% of the world 
in the fields of “Clinical Medicine”, “Pharmacology 
& Toxicology”, and “Social Sciences”. In the same 
report, only three scientists from TUMS have been 
listed as 1% top scientists who are ranked in the field 
of PTP. Considering citations of the papers there are 
almost 10 times increase in the number of citations   
during the last 10 years. Regarding international 
collaboration, as reported by NewScientists (2) and 
UK’s  Royal  Society  (3),  scientific  collaboration 
has increased between USA and Iran. Between 
the periods 1996 to 2008, co-authored papers 
between these two countries increased from 388 
to 1,831 papers (3). Of course, data coming from 
Scopus (5) show no significant change in the rate of 
international collaboration for Iran during the years. 
According to UK’s Royal Society, while the USA, 
Europe and Japan demonstrate a growing propensity 
to collaboration with global partners, China, 
Turkey and Iran are proportionally decreasing their 
collaborations. Meanwhile other growing scientific 
nations such as Saudi Arabia and South Africa are 
increasing their relative collaborations (3).
By examination of the relative production of 
science in the region and the world, a significant 
improvement was found in the field of PTP where 
the role of Iranian scientists cannot be ignored. 
When different subjects of this field are examined, 
it is clear that most of improvements have been 
in pharmacology, drug discovery, toxicology, 
and pharmaceutics. Interestingly, Iran is ranked 
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pharmacology, drug discovery, toxicology (7). 
Data, especially those driven from ESI (6) about 
top subjects of research and top scientists of 
TUMS and those mentioned above led us to the 
conclusion that PTP in Iran is growing very fast 
with more impact on the country science growth. 
Thus, responsibilities of the scientists in the field of 
PTP compared to other areas is higher and thus it is 
time to review previous achievements for a better 
plan for the future and define strategies. The main 
problem is that H-index of Iran has not increased 
with the same speed as its publication number. For 
instance a comparison between Iran and Turkey 
or Malaysia in PTP in 2009, show that H-index of 
Turkey is 61, Iran is 37, and Malaysia is 30 while 
number of publications in Iran is 563, Turkey is 385, 
and Malaysia is 165 (7). Comparing the number of 
publications with that of H-index indicates Iran has 
to improve quality of its publications to get regular 
higher citations during the years. H-index assesses 
both quantity and quality of studies and thus an 
academic must have substantial number of papers 
to get a high h-index. If an academic or country 
show good citation metrics, it is very likely to make 
a marked impact on the field. The other point that 
should be emphasized is international collaboration 
that does not match with growth of science in PTP. 
Growth of science as a global enterprise to solve 
global problems depends on data collected from all 
around the world. It means increasing international 
collaboration is a must and should be the main aim 
of the strategy of all countries. Other important 
points are to encourage working in specific lines of 
research, team working by defining  team members’ 
exact tasks and commitments, dedication to finish 
long-term projects and to report in a single article 
to get higher citation, improving systematic search 
and methodology to avoid repetition of other works 
that do not add to current knowledge of the world 
or even Iran, considering the country demand in 
all researches, publishing in indexed journals, 
introducing novel methods and study models, 
conducting systematic review/meta-analysis 
studies, avoiding delay between completion of 
the study and the final publication of manuscripts 
(this is the role of study supervisors), having 
collaboration of students investigation by meeting 
higher standards of ethics (8), improving criticism 
by holding journal clubs, always being in-time for 
all deadlines, higher honesty in thinking, collection 
and analysis of data, and writing whether they do 
not support their own theories, trying to get the idea 
from public and patent databases and industries, 
making sure that the project would contribute to the 
advancement of knowledge in the field of PTP by 
validating or contradicting previous knowledge and 
considering cost-benefit issues in the field. 
Furthermore it is recommended, if a new compound 
is synthetized chemically or extracted from the herb, 
after basic laboratory investigations and animal tests 
and defining efficacy and safety, the study must be 
continued by joining to other teams from clinic to 
evaluate safety, dose range, and side effects of this 
new treatment in a small group of healthy volunteers 
in phase 1 clinical trial; then it must be continued by 
determination of the safety and efficacy of the new 
treatment in larger and longer trials in patients (phases 
2 and 3). Then, the efficacy and safety of this new 
treatment with existing treatments should be compared 
to complete customers’ needs and expectations.
 This is an example of a novel research and 
publications with wide applications that meet a 
clearly defined market need. Of course in the recent 
years, there have been real examples for what I 
described. Introduction of Samelil (9) and Setarud 
(10) as new successful drugs have been completed 
by a joint cooperation of scientists in the field of 
PTP and those from different aspects of clinic that 
resulted in introduction of a product to market. 
Once again, Iranian scientists in the field of PTP 
have done a good job but there are still more to be 
done.
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